NASDAQ: CDTConduit Pharmaceuticals Inc Stock
$2.84-0.11 (-3.73%)
Updated Oct 31, 2025
CDT Price
$2.84
Fair Value Price
N/A
Market Cap
$1.09M
52 Week Low
$2.72
52 Week High
$2,198.40
P/E
0x
P/B
0.31x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$19.65M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
1.26
Operating Cash Flow
-$12M
Beta
0.03
Next Earnings
Nov 12, 2025
Ex-Dividend
N/A
Next Dividend
N/A
CDT Overview
Murphy Canyon Acquisition Corporation is a "blank check" company formed to effect mergers, stock purchases, or similar combinations with one or more businesses. It targets the construction/homebuilding companies and adjacent businesses targeting the real estate space. Murphy Canyon Acquisition was incorporated in 2021 and is headquartered in San Diego, CA.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine CDT's potential to beat the market
DSell
- Stocks with a Zen Rating of Sell (D) had an average loss of -4.50% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
CDT
Ranked#404 of 488
Ranked#404 of 488
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $7.65 | A | |
| $93.48 | A | |
| $14.66 | A |
Be the first to know about important CDT news, forecast changes, insider trades & much more!
CDT News
Overview
Due Diligence Score
–
Industry Average (23)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how CDT scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
CDT is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
CDT is good value based on its book value relative to its share price (0.31x), compared to the US Biotechnology industry average (4.99x)
P/B vs Industry Valuation
CDT is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more CDT due diligence checks available for Premium users.
Valuation
CDT price to earnings (PE)
For valuing profitable companies with steady earnings
Company
0x
Industry
-9.17x
Market
41.55x
CDT price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.31x
Industry
4.99x
CDT is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
CDT's financial health
Profit margin
Revenue
$0.0
Net Income
-$6.0M
Profit Margin
0%
CDT's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$8.0M
Liabilities
$4.5M
Debt to equity
1.26
CDT's short-term assets ($6.39M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
CDT's short-term assets ($6.39M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
CDT's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$2.6M
Investing
-$1.0k
Financing
$3.8M
CDT's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
CDT vs Biotech Stocks
Conduit Pharmaceuticals Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.